SEC Form 4 · accession 0001213900-18-005372
NEXEON MEDSYSTEMS INC · NXNN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Rosellini
Officer — Chief Executive Officer · Director
Period of report
Feb 28, 2018
Accepted (ET)
May 1, 2018 · 8:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001416172
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPTIONSF1 | $0.76 | Feb 28, 2018 | A | 250,000 | A | Feb 28, 2018 | Feb 28, 2022 | COMMON STOCK | 250,000 | 250,000 | D |
| OPTIONSF2 | $0.76 | Feb 28, 2018 | A | 900,000 | A | Mar 1, 2018 | Mar 1, 2023 | COMMON STOCK | 900,000 | 900,000 | D |
Explanation of responses
- F1On February 28, 2018, and pursuant to the Issuer's 2016 Omnibus Incentive Plan, the Issuer granted to the Reporting Person an incentive stock option (the "Incentive Option") to purchase 250,000 shares of the Issuer's restricted common stock, at a price of $0.76 per share, as compensation for service as Chief Executive Officer of the Company. The option to purchase 125,000 shares of the Issuer's restricted common stock became immediately exercisable on the date of issue and the option to purchase the remaining 125,000 shares of the Issuer's restricted common stock vests on the anniversary of the grant date. The option to purchase shares of the Issuer's restricted common stock expire three (3) years from the date they become exercisable pursuant to the grant vesting schedule. The fair value of the options was determined to be $49,132 using the Black- Scholes Option Pricing Model.
- F2On February 28, 2018, and pursuant to the Issuer's 2016 Omnibus Incentive Plan, the Issuer granted to the Reporting Person a non-qualified stock option (the "NQS Option") to purchase 900,000 Issuer's restricted common stock at a price of $0.76 per share, as compensation for service as Chief Executive Officer of the Company. The NQS Option vests in equal monthly amounts of 37,500 beginning on March 1, 2018. The option to purchase Issuer's restricted common stock expire three (3) years from the date they become exercisable pursuant to the grant vesting schedule. The fair value of the options was determined to be $176,877 using the Black- Scholes Option Pricing Model.